Abstract: The present invention is directed to a method for coating catheter balloons with a defined amount of a pharmacologically active agent, wherein the coating method uses a coating device having a volume measuring device for releasing a measurable amount of a coating solution by means of a dispensing device specifically onto the surface of the catheter balloon.
Type:
Grant
Filed:
February 9, 2011
Date of Patent:
November 24, 2015
Assignee:
Hemoteq AG
Inventors:
Erika Hoffmann, Roland Horres, Volker Faust, Helmut Schreiber, Armin Von Holst, Michael Hoffmann
Abstract: The present invention provides a crosslinked amine and amide polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritis, irritable bowel syndrome-diarrhea (IBS-D), bile acid malabsorption, and the like.
Type:
Grant
Filed:
February 24, 2011
Date of Patent:
November 10, 2015
Assignee:
Relypsa, Inc.
Inventors:
Jordan Kopping, Kalpesh Biyani, Eric Connor, Scott Hecker, Inez Lees, Grace Huynh, Faleh Salaymeh, Hongmin Zhang, David Bergbreiter, Paul Mansky, YongQi Mu, Michael James Cope, Elizabeth Goka, Angela Lee, Deidre Madsen, Jun Shao
Abstract: The present invention relates to a cosmetic composition containing a combination i) of at least one screening agent of the dibenzoylmethane derivative type and ii) of at least one particular hydrophilic or water-soluble merocyanin UV-screening agent, especially corresponding to one of the formulae (I) or (II) below: in which at least one or two of the radicals contain: either an alkylsulfonate radical in its acid or salified form, or one or two hydroxyl radicals. The invention also relates to a process for the radiation-photostabilization of at least one screening agent of the dibenzoylmethane derivative type with an effective amount of at least one particular hydrophilic or water-soluble merocyanin UV-screening agent, especially corresponding to one of the formulae (I) or (II).
Abstract: The present invention relates to a filler composition for tissue reinforcement, including hyaluronic acid and alkylene diamine crosslinked hydrogel. The filler composition exhibits the positive physical properties required for tissue reinforcement, such as biocompatibility and swelling ability, as well as useful effects in that the same can remain in vivo for a long time.
Type:
Grant
Filed:
July 11, 2011
Date of Patent:
April 28, 2015
Assignees:
Shin Poong Pharmaceutical Co., Ltd., Postech Academy-Industry Foundation
Inventors:
Il Hwan Cho, Eui Jin Hwang, Moo Seok Seo, Young Soo Park, Byung Su Kim, Sei Kwang Hahn, Jung Kyu Park, Jun Seok Yeom, Eun Ju Oh
Abstract: A graft copolymer with pH dependent behavior of formula 1 Comprises, (i) a backbone having the formula 1 [A(X)B(Y)C(z)] wherein (A) is diol, (B) is dicarboxylic acid or acid anhydride and (C) is monomer containing pendent unsaturation such that (x)=41-45%, (y)=49-53% (z)=4-7% by mole; and (ii) a graft which is a polymer of the basic monomer (D) which comprises “w” weight percent of the total weight of said graft copolymer such that ‘w’ is 22-52%. The graft copolymers do not swell/dissolve at neutral and basic pH and swell/dissolve at acidic pH. The polymers are useful as protective coating for pharmaceutical dosage forms and as excipient in the development of extended release drug delivery systems.
Type:
Grant
Filed:
March 9, 2011
Date of Patent:
April 21, 2015
Assignee:
Council of Scientific & Industrial Research
Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.
Type:
Grant
Filed:
September 2, 2010
Date of Patent:
March 3, 2015
Assignee:
Ajou University Industry-Academic Cooperation Foundation
Inventors:
Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park, Eu-Gene Lih
Abstract: Provided are hair processing agents capable of permanent waving hair even at a neutral to weakly acidic pH range that causes less irritation to the skin, and hair processing agents in which an unpleasant odor is masked. Hair processing agents contain at least one compound represented by the formula (2). Hair processing agents contain a compound of the formula (2) and at least one compound (ii) selected from thioglycolic acid, thiolactic acid, cysteine, acetylcysteine, cysteamine, acylcysteamine, salts thereof and ester derivatives thereof. Hair processing agents contain a compound of the formula (2), a surfactant and water, and are emulsified. Hair processing agents contain a compound of the formula (2) and a specific perfume.
Abstract: The present invention relates to nicotine lozenge compositions comprising reduced levels of buffering agents from traditional nicotine lozenges and which provide optimal oral pH and prompt nicotine absorption in a smaller, more convenient dosage form.
Abstract: The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Abstract: Liquid formulations of imidoalkanepercarboxylic acids, in the form of aqueous dispersions comprising, in percentages by weight relative to the total weight of the composition: A) from ?7% to 40% and preferably from 10% to 20% of imidoalkanepercarboxylic acids having the general formula (I), the said imidoalkanepercarboxylic acids being in the ? form and having a dissolution time, determined via the test of the rate of dissolution at a temperature of 40° C. or 18° C., of not more than 5 minutes when determined at 40° C. or 15 minutes when determined at 18° C., for an amount of dissolved acid equal to 99% of the theoretical amount; B) from 0.001% to 0.9% of a nonionic surfactant; the said dispersions having a viscosity of not more than 2000 mPa·sec at 25° C. by applying a shear rate of 20 s?1; in which the dissolution time of the component A), determined via the test of the rate of dissolution at a temperature of 40° C. or 18° C., is not more than 5 minutes when determined at 40° C.
Abstract: A particulate co-processed composition comprising microcrystalline cellulose and at least one sugar alcohol is disclosed. A preferred sugar alcohol is mannitol. The composition has an improved compactability profile, lubricant sensitivity, and ejection profile compared to microcrystalline cellulose and the at least one sugar alcohol, either alone or in combination as a simple dry blend, in the preparation of solid dosage formulations, such as tablets. Tablets comprising the particulate co-processed composition, an active, and, optionally, one or more other excipients, and method for their preparation, are also disclosed.
Type:
Grant
Filed:
October 26, 2007
Date of Patent:
January 13, 2015
Assignee:
FMC Corporation
Inventors:
Jian-Xin Li, Brian Carlin, Thomas Ruszkay
Abstract: This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing metoprolol or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.
Abstract: The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
Type:
Grant
Filed:
February 5, 2013
Date of Patent:
November 18, 2014
Assignee:
Hoffman-La Roche Inc.
Inventors:
Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
Abstract: The invention provides a hollow nano-particle comprising a crosslinked shell and a void core; and a preparation method thereof. The hollow nano-particle may be used in rubber composition, tire product, and pharmaceutical delivery system etc.
Type:
Grant
Filed:
December 20, 2006
Date of Patent:
November 4, 2014
Assignee:
Bridgestone Corporation
Inventors:
Xiaorong Wang, Mindaugas Rackaitis, Pat Sadhukhan
Abstract: A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase inhibitor), and a concentration enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concentration-enhancement of the CETP inhibitor when administered to an aqueous use environment.
Type:
Grant
Filed:
May 22, 2006
Date of Patent:
September 9, 2014
Assignee:
Bend Research, Inc.
Inventors:
Dwayne Thomas Friesen, Bruno Caspar Hancock, Rodney James Ketner, David Keith Lyon, James Alan Shriver Nightingale, Ravi Mysore Shanker
Abstract: A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.
Type:
Grant
Filed:
April 16, 2014
Date of Patent:
September 9, 2014
Assignee:
Clarus Therapeutics, Inc.
Inventors:
Robert E. Dudley, Panayiotis P. Constantinides
Abstract: A gastroretentive, extended release composition which floats and swells at acidic pH prevalent in the stomach. The composition includes a pH dependent graft copolymer, a gellable polymer, a therapeutic agent, a gas generating system and pharmaceutically acceptable ingredients. The disclosed composition is useful to deliver the therapeutic agent within the stomach for an extended period of time.
Type:
Grant
Filed:
September 10, 2012
Date of Patent:
August 19, 2014
Assignee:
Council of Scientific & Industrial Research
Abstract: A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.
Type:
Grant
Filed:
September 13, 2013
Date of Patent:
July 15, 2014
Assignee:
Clarus Therapeutics, Inc.
Inventors:
Robert E. Dudley, Panayiotis P. Constantinides
Abstract: A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.
Type:
Grant
Filed:
August 14, 2012
Date of Patent:
July 15, 2014
Assignee:
Clarus Therapeutics, Inc.
Inventors:
Robert E. Dudley, Panayiotis P. Constantinides